The stocks of WAT have been issued with a rating of hold which has been presented by close to sixteen different research equities covering the firm. According to a report, four of the investment analysts have already given the stocks a rating of sell, while nine of them have given it a recommendation of hold. The price target of the company over the period of a single year has been $224.09.
There have been quite a few research firms that have already commented on the stocks of WAT. Smith Barney Citigroup has provided the company with a rating of neutral after it was previously a rating of sell- in a research note published on the 16th of December. Wells Fargo & Company has also reduced the shares of the company from a rating of equal weight to underweight- along with a price target of $235 set in a 7th January research note.
TheStreet has also increased the rating of the company from c to a-, in a 2nd February research report. In the end, Cleveland Research also ended up raising the shares of the company from a rating of underperform to a rating of buy in a 17th December research report.
The Quarterly Estimate of WAT
The stocks of WAT traded on Friday at $266.44. The market cap of the firm has been set at $16.57 billion, with a 33.18 PE ratio, and an 8.79 PEG ratio. The moving average price of the company over 50 days is $275.96, with a moving average price over 200 days set at $236.59. The year low of the firm over a year has been $154.39, while the year high of the company is $299.06.
WAT previously posted their results of quarterly earnings on the 1st of February. The supplier of medical instruments reported an EPS of $3.65 which was more than the consensus estimate of $2.89. The net margin of the company is 22.61%, with a -349.31% return on its equity.
